KR102175929B9 - Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3a - Google Patents
Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3aInfo
- Publication number
- KR102175929B9 KR102175929B9 KR1020190017651A KR20190017651A KR102175929B9 KR 102175929 B9 KR102175929 B9 KR 102175929B9 KR 1020190017651 A KR1020190017651 A KR 1020190017651A KR 20190017651 A KR20190017651 A KR 20190017651A KR 102175929 B9 KR102175929 B9 KR 102175929B9
- Authority
- KR
- South Korea
- Prior art keywords
- brn3a
- diagnosis
- treatment
- composition
- thyroid cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/12—Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190017651A KR102175929B1 (en) | 2019-02-15 | 2019-02-15 | Composition for diagnosis and treatment of thyroid cancer comprising Brn3a |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190017651A KR102175929B1 (en) | 2019-02-15 | 2019-02-15 | Composition for diagnosis and treatment of thyroid cancer comprising Brn3a |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20200099721A KR20200099721A (en) | 2020-08-25 |
KR102175929B1 KR102175929B1 (en) | 2020-11-06 |
KR102175929B9 true KR102175929B9 (en) | 2022-05-10 |
Family
ID=72242032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190017651A KR102175929B1 (en) | 2019-02-15 | 2019-02-15 | Composition for diagnosis and treatment of thyroid cancer comprising Brn3a |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102175929B1 (en) |
-
2019
- 2019-02-15 KR KR1020190017651A patent/KR102175929B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20200099721A (en) | 2020-08-25 |
KR102175929B1 (en) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276808A (en) | Compositions and methods for cancer treatment | |
EP3424505A4 (en) | Preparation and composition for treatment of malignant tumors | |
IL268814A (en) | Compositions and methods for treatment of cancer | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
FI3773689T3 (en) | Antigenic peptides for prevention and treatment of cancer | |
EP4186519A4 (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
IL289787A (en) | Antibody combinations for treatment of cancer in specific patients | |
IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
IL290130A (en) | Treatment of immune evasive tumors | |
EP4010022A4 (en) | Compositions and methods for diagnosis and treatment of bladder cancer | |
IL274008A (en) | Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment | |
IL288787A (en) | Methods and compositions for improving outcomes of cancer patients | |
IL289251A (en) | Methods and compositions for treatment of pancreatic cancer | |
IL255169A0 (en) | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer | |
IL274007A (en) | Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same | |
IL272147A (en) | Methods and compositions for the treatment of cancer | |
GB201820994D0 (en) | Methods of treatment and diagnosis of tumours | |
KR102175929B9 (en) | Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3a | |
FI3630112T3 (en) | Combination of regorafenib and nivolumab for treating cancer | |
IL280262A (en) | Compositions and methods for the treatment of cancer | |
EP3987032A4 (en) | Methods and compositions for the treatment of cancer | |
IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
EP3794040A4 (en) | Compositions and methods for diagnosis and treatment of cancer | |
IL276228A (en) | Compounds and compositions for the treatment of pain | |
KR102373488B9 (en) | Composition for immune enhancing or preventing or treating of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
G170 | Re-publication after modification of scope of protection [patent] |